We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

CELLAVISION AB

CellaVision AB provides digital solutions for medical microscopy in the field of hematology, with its product portfol... read more Featured Products: More products

Download Mobile App




Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions

By LabMedica International staff writers
Posted on 07 Feb 2024
Print article
Image: The DI-60 automated digital cell morphology analyzer developed by Sysmex in collaboration with CellaVision (Photo courtesy of Sysmex)
Image: The DI-60 automated digital cell morphology analyzer developed by Sysmex in collaboration with CellaVision (Photo courtesy of Sysmex)

Sysmex Corporation (Kobe, Japan) has entered into a strategic alliance agreement with CellaVision (Lund, Sweden) to advance hematology solutions. This collaboration aims to expand Sysmex's product range, including the development of cutting-edge cell morphology analyzers. Together, Sysmex and CellaVision will strive to improve the efficiency and standardization of testing workflows in hematology, enhance the accuracy of cell morphology classification, and provide valuable support in diagnostic processes.

The partnership between Sysmex and CellaVision has spanned 20 years, focusing on hematology, which involves the analysis of blood cells such as red and white blood cells in terms of their count, types, and sizes. This collaboration began in 2001 when Sysmex entered a sales alliance for CellaVision’s cell morphology analyzers. In 2013, Sysmex introduced the DI-60 Automated Digital Cell Morphology Analyzer, a product of its collaboration with CellaVision. This system, when integrated with Sysmex’s hematology analyzers, automates up to the cell morphology analysis stage, significantly streamlining and standardizing testing workflows in clinical laboratories worldwide.

The renewed partnership between the two companies aims to enhance their product offerings, particularly in next-generation cell morphology analyzers. They have agreed to extend their collaborative efforts to advance hematology solutions and maintain their agreement until 2038. Leveraging a stable, long-term collaborative framework, Sysmex plans to utilize its expertise in optimizing testing workflows in hematology, while CellaVision will contribute its advanced digital imaging and analysis technologies. These joint efforts are intended to further improve efficiency and standardization in testing workflows and increase clinical value by providing more precise cell morphology classification to aid in diagnoses.

“We are pleased to expand our alliance with CellaVision since 2013,” said Takashi Ono, Member of the Managing Board and Senior Executive Officer, Managing Director at Sysmex Corporation. “This alliance enables us to further enhance our leadership position in hematology worldwide. We will collaborate wider and deeper to increase value to our customers by portfolio expansion in digital cell morphology.”

"This alliance marks an important milestone in our joint mission to elevate healthcare and evolve microscopy together for a better healthcare journey,” said Simon Østergaard, President & CEO, CellaVision AB. “We are delighted to further strengthen our ties with Sysmex to continue the global adoption of advanced digital cell morphology solutions integrated with the leading cell counter offerings of Sysmex.”

Related Links:
Sysmex Corporation
CellaVision 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.